Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against VNET, and Assertio and Encourages Investors to Contact the Firm
12 janv. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
ASSERTIO SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Assertio To Contact Him Directly To Discuss Their Options
10 janv. 2024 10h45 HE
|
Faruqi & Faruqi LLP
If you suffered losses exceeding $25,000 investing in Assertio stock or options between March 9, 2023 and November 8, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Assertio Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ASRT
09 janv. 2024 14h03 HE
|
The Rosen Law Firm PA
NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Assertio...
ASSERTIO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Assertio Holdings, Inc. and Encourages Investors to Contact the Firm
08 janv. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against...
Assertio Reports Second Quarter 2023 Financial Results, Closes Spectrum Acquisition
03 août 2023 16h04 HE
|
Assertio Holdings, Inc.
Second Quarter Net Product Sales Increase 13% Year-Over-Year, Generates $18.6 Million in Cash Flow from Operations Acquisition Expected to be Significantly Accretive to Adjusted EPS in 2024 LAKE...
Assertio Holdings, Inc. to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
27 avr. 2023 09h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., April 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction
25 avr. 2023 06h00 HE
|
Assertio Holdings, Inc.; Spectrum Pharmaceuticals, Inc.
Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio’s Omni-Channel...
Assertio Reports Fourth Quarter and Full Year 2022 Financial Results
08 mars 2023 16h01 HE
|
Assertio Holdings, Inc.
Net Product Sales Increase 55% in the Fourth Quarter, 42% for the Full Year Full Year Net Income Increases to $109.6 Million, Non-GAAP Adjusted EBITDA Increases to $101.6 Million Cash Flows from...
Assertio Holdings, Inc. Announces Preliminary Fourth Quarter and Full Year 2022 Results
21 févr. 2023 07h00 HE
|
Assertio Holdings, Inc.
Year-over-Year Net Product Sales Increased at Least 54% for the Fourth Quarter and 41% for the Full Year Cash Flows from Operations Was at Least $26 Million for the Fourth Quarter and $78 Million for...
Assertio to Participate in the 2023 SVB Securities Global Biopharma Conference
08 févr. 2023 08h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...